Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01764737 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS
A Phase 1 study of Multiple Sclerosis, sponsored by Vaccinex.
- Completed
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 10
- Study locations
NCT01764737 is a Phase 1 study of Multiple Sclerosis that has completed, run by Vaccinex. The registered enrollment target is 50 participants, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 9 states.
The verdict
NCT01764737, a Phase 1 study of Multiple Sclerosis, has completed, sponsored by Vaccinex.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis. The escalation part of the study will determine the maximum tolerated dose (MTD) or the Maximum Administered Dose if no MTD is found.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG VX15/2503
Study Locations (10)
New York
- MS Center of Northeastern NY/Empire Neurology - Latham
- University of Rochester Medical Center - Rochester
Alabama
- North Central Neurology Associates, PC - Cullman
Colorado
- University of Colorado Hospital, Aschutz Inpatient Pavilion - Aurora
Indiana
- Indiana University Health Neuroscience Center - Indianapolis
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Wayne State University - University Health Center - Detroit
North Carolina
- The Neurological Institute, PA - Charlotte
Ohio
- The Cleveland Clinic Foundation - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2012-12 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01764737
The ClinicalTrials.gov registry entry for NCT01764737 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 585-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (91% lower). The listed sponsor is Vaccinex, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01764737 reports 10 study locations spanning 9 distinct geographic areas - top geographies include New York, Alabama, Colorado.
Frequently Asked Questions
What is clinical trial NCT01764737 about?
NCT01764737 is a clinical study titled "Evaluation of Safety, Tolerability, and PK of VX15/2503 In Patients With MS". The purpose of this study is to evaluate the safety and tolerability of IV administration of VX15/2503 in patients with multiple sclerosis. The escalation part of the study will determine the maximum tolerated dose (MTD) or the Maximum Administered Dose if no MTD is found.
What is the current status of trial NCT01764737?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2012-12. Estimated completion is 2014-11.
What conditions does trial NCT01764737 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT01764737?
The interventions under investigation include: Placebo (DRUG), VX15/2503 (DRUG).
Who is sponsoring clinical trial NCT01764737?
This trial is sponsored by Vaccinex, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01764737 being conducted?
This trial has 10 study locations across Alabama, Colorado, Indiana, Kansas, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
Vancomycin Study in Multiple Sclerosis (MS)
RECRUITING · Phase 1
-
Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer
RECRUITING · Phase 1
-
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RECRUITING · Phase 1
-
Molecular Imaging of NET Using [C-11]MRB-PET in MS
RECRUITING · Phase 1
-
Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.